Sphere Bio
Cambridge
About Sphere Bio
Sphere Bio provides instruments, consumables, and reagents for single-cell analysis and isolation, leveraging picodroplet microfluidic technology. Its platforms, including Cyto-Mine® and Cyto-Mine® Chroma, support high-throughput screening, verified monoclonality, and precise single-cell dispensing for applications in biologics discovery, cell line development, cell therapy, and synthetic biology. The company also offers a range of assay kits, such as Cyto-Cellect® products, to detect cell productivity and viability for human and mouse antibodies, as well as Fc fusion proteins. Sphere Bio’s solutions integrate seamlessly into laboratory workflows, allowing researchers to analyze millions of cells efficiently without compromising viability. Its technology is built around stable, biocompatible picodroplets that encapsulate individual cells for large-scale single-cell experiments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $61.2M
- Last round: Series Unknown (Oct 2021)
- Website: spherebio.com
- Phone: 441223804210
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/sphere-bio-108051 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.